|
Sandra, could be some IMNR news on June 11 at their annual meeting (in my opinion). Wouldn't be surprised to see a run-up to 12.5-13 in the next week from its 11.25 close today. Also, big things expected from the World Aids conference on June 28-July 3 in Geneva. IMNR is presenting 3 papers on July 2. IMNR is the leader in Immune-based therapy for aids. The medical community has come full-circle to recognize that immune based therapies (such as IMNR's REMUNE) are needed to complement antiviral therapy (e.g. azt, viracept) in order to combat the aids virus. Wall Street has yet to come on board, and is taking a wait-and-see attitude...so there's value in IMNR. Wall Street instead will wait for fda approval. I'm willing to gamble that fda approval will come. The drug has no toxicity (side effects), is easy to administer (quarterly injections rather than numerous daily pills), and, above all, works (stimulates an hiv-specific immune response). IMNR is years ahead of other companies in this therapeutic approach, and will be the first to gain approval. But it's a long-term investment. I'm holding it for at least 3 years until it matures to a 100-200 dollar company. Seems as if people on this board are day traders at heart (nothing wrong with that), but if folks are looking long-term, and like some risk with great reward, you can't go wrong with IMNR. MEGW is my short-term play (i.e., 1 month to 18 months). Good luck. |
